Company
Headquarters: Incheon, South Korea
Employees: 3,247
CEO: Mr. John Chongbo Rim
₩55.141 Trillion
KRW as of Jan. 1, 2024
US$42.59 Billion
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Samsung Biologics Co., Ltd. engages in the contract manufacturing organization business for biopharmaceuticals products. It is involved in the provision of contract development organization services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company has a strategic partnership agreement with Kineta, Inc. Samsung Biologics Co., Ltd. was founded in 2011 and is headquartered in Incheon, South Korea.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Samsung Biologics Co.,Ltd. has the following listings and related stock indices.
Stock: KRX: 207940 wb_incandescent